



November 25, 2021
JCR Pharmaceuticals Co., Ltd.

Translation

Notice Regarding Change in Major Shareholders

Nov. 25, 2021 -- JCR Pharmaceuticals Co., Ltd. (TSE 4552; Chairman and President: Shin Ashida; "JCR") announced today that there has been a change in the Company's major shareholders as follows.

1. Background to the change

JCR received a notification from Kissei Pharmaceutical Co., Ltd., a shareholder of the Company, that it had sold a portion of the Company's shares (413,200 shares) that it held. As a result, there has been a change in the Company's major shareholders as of November 25, 2021, and Kissei Pharmaceutical Co., Ltd. has ceased to be a major shareholder of the Company.

2. Overview of the change in shareholders

(1) Name	Kissei Pharmaceutical Co., Ltd.
(2) Address	19-48, Yoshino, Matsumoto, Nagano, Japan
(3) Name and title of representative	Mutsuo Kanzawa, Chairman and CEO
(4) Business type	Manufacture and sales of pharmaceutical products
(5) Capital	24,356 million yen

3. Number of voting rights held by the shareholder (number of shares held) and ratio of its voting rights to the number of voting rights of all shareholders before and after the change

	Number of voting rights (number of shares held)	Ratio to number of voting rights of all shareholders	Major shareholder ranking
Before the change (as of September 30, 2021)	128,200 (12,820,000 shares)	10.33%	2nd
After the change (as of November 25, 2021)	124,068 (12,406,800 shares)	9.99%	2nd

*1. The number of shares held before the change corresponds to the figure listed on the register of shareholders as of September 30, 2021. The number of shares held after the change is listed based on the notification from the shareholder regarding the sale.

*2. The ratio to the voting rights of all shareholders before and after the change has been calculated using the number of voting rights of all shareholders as of September 30, 2021 (1,240,727) as a denominator.

4. Future outlook

This change in major shareholders will have no impact on the business of renal anemia drugs conducted by Kissei Pharmaceutical Co., Ltd. and JCR.

About JCR Pharmaceuticals Co., Ltd.

JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceuticals company that is redefining expectations and expanding possibilities for people with rare and genetic diseases worldwide. We continue to build upon our 46-year legacy in Japan while expanding our global footprint into the US, Europe, and Latin America. We improve patients' lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, Fabry disease, MPS II (Hunter syndrome), acute graft-versus host disease, and renal anemia. Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), Hunter syndrome, Pompe disease, and more. JCR strives to expand the possibilities for patients while accelerating medical advancement at a global level. Our core values – reliability, confidence, and persistence – benefit all our stakeholders, including employees, partners, and patients. Together we soar. For more information, please visit <https://www.jcrpharm.co.jp/en/site/en/>.

Cautionary Statement Regarding Forward-Looking Statements

This document contains forward-looking statements that are subject to known and unknown risks and uncertainties, many of which are outside our control. Forward-looking statements often contain words such as “believe,” “estimate,” “anticipate,” “intend,” “plan,” “will,” “would,” “target” and similar references to future periods. All forward-looking statements regarding our plans, outlook, strategy and future business, financial performance and financial condition are based on judgments derived from the information available to us at this time. Factors or events that could cause our actual results to be materially different from those expressed in our forward-looking statements include, but are not limited to, a deterioration of economic conditions, a change in the legal or governmental system, a delay in launching a new product, impact on competitors' pricing and product strategies, a decline in marketing capabilities relating to our products, manufacturing difficulties or delays, an infringement of our intellectual property rights, an adverse court decision in a significant lawsuit and regulatory actions.

This document involves information on pharmaceutical products (including those under development). However, it is not intended for advertising or providing medical advice. Furthermore, it is intended to provide information on our company and businesses and not to solicit investment in securities we issue.

Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the factors that could cause actual results to differ materially, even if new information becomes available in the future.

Contact:

Investors & Media:

JCR Pharmaceuticals Co., Ltd.

Corporate Communications

ir-info@jcrpharm.co.jp

###